(Q37853793)

24 August 2017

1 reference

title

Challenges for allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia in the era of tyrosine kinase inhibitors (English)

1 reference

stem cell transplantation

24 August 2017

main subject

chronic myeloid leukemia

0 references

leukemia

1 reference

based on heuristic

inferred from title

1 reference

7

Ulrike Bacher

1 reference

24 August 2017

6

Michele Baccarani

1 reference

24 August 2017

Anthony Oyekunle

1

1 reference

24 August 2017

Evgeny Klyuchnikov

2

1 reference

24 August 2017

Sunday Ocheni

3

1 reference

24 August 2017

Nicolaus Kröger

4

1 reference

24 August 2017

Axel R Zander

5

1 reference

24 August 2017

publication date

17 March 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

126

1 reference

24 August 2017

issue

1

1 reference

24 August 2017

page(s)

30-39

1 reference

Hematopoietic stem cell transplantation for hematological malignancies in Europe.

24 August 2017

cites work

1 reference

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

21 January 2018

1 reference

Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study

21 January 2018

1 reference

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

21 January 2018

1 reference

Current and emerging treatment options in chronic myeloid leukemia

21 January 2018

1 reference

Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study

21 January 2018

1 reference

Allo-SCT conditioning for myelodysplastic syndrome and acute myeloid leukemia with clofarabine, cytarabine and ATG.

21 January 2018

1 reference

Pretransplant imatinib can improve the outcome of nonmyeloablative stem cell transplantation without increasing the morbidity in Philadelphia chromosome-positive chronic myeloid leukemia

21 January 2018

1 reference

Complete remission from chronic myelogenous leukemia--blastic crisis caused by reduced intensity stem cell transplantation following partial remission due to imatinib

21 January 2018

1 reference

Prior treatment with the tyrosine kinase inhibitors dasatinib and nilotinib allows stem cell transplantation (SCT) in a less advanced disease phase and does not increase SCT Toxicity in patients with chronic myelogenous leukemia and philadelphia pos

21 January 2018

1 reference

A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase.

21 January 2018

1 reference

Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy

21 January 2018

1 reference

Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT.

21 January 2018

1 reference

Who with chronic myelogenous leukemia to transplant in the era of tyrosine kinase inhibitors?

21 January 2018

1 reference

Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host dis

21 January 2018

1 reference

Second-generation tyrosine kinase inhibitors in the post-transplant period in patients with chronic myeloid leukemia or Philadelphia-positive acute lymphoblastic leukemia.

21 January 2018

1 reference

Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplantation: prognostic significance of the dose of CD3(+) and CD4(+) lymphocytes.

21 January 2018

1 reference

Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia.

21 January 2018

1 reference

EBMT activity survey 2004 and changes in disease indication over the past 15 years.

21 January 2018

1 reference

The changing scene of allogeneic stem cell transplantation for chronic myeloid leukemia--a report from the German Registry covering the period from 1998 to 2004.

21 January 2018

1 reference

A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group.

21 January 2018

1 reference

Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

21 January 2018

1 reference

Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase.

21 January 2018

1 reference

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

21 January 2018

1 reference

KIR2DS5 is associated with leukemia free survival after HLA identical stem cell transplantation in chronic myeloid leukemia patients.

21 January 2018

1 reference

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

21 January 2018

1 reference

Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV.

21 January 2018

1 reference

Current role of stem cell transplantation in chronic myeloid leukaemia

21 January 2018

1 reference

Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia

21 January 2018

1 reference

Late mortality and relapse following BuCy2 and HLA-identical sibling marrow transplantation for chronic myelogenous leukemia.

21 January 2018

1 reference

21 January 2018

1 reference

Dose-reduced conditioning for allografting in 44 patients with chronic myeloid leukaemia: a retrospective analysis

21 January 2018

1 reference

Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase

21 January 2018

1 reference

Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML.

21 January 2018

1 reference

Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis

21 January 2018

1 reference

Treosulfan and fludarabine low-toxicity conditioning for allogeneic haematopoietic stem cell transplantation in chronic myeloid leukaemia.

21 January 2018

1 reference

Reduced-intensity allogeneic transplantation combined with imatinib mesylate for chronic myeloid leukemia in first chronic phase.

21 January 2018

1 reference

Imatinib therapy prior to myeloablative allogeneic stem cell transplantation

21 January 2018

1 reference

The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia

21 January 2018

1 reference

Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease

21 January 2018

1 reference

Imatinib for refractory chronic graft-versus-host disease with fibrotic features.

21 January 2018

1 reference

Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner

21 January 2018

1 reference

Effects of imatinib on normal hematopoiesis and immune activation.

21 January 2018

1 reference

Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia

21 January 2018

1 reference

Prediction of relapse by day 100 BCR-ABL quantification after allogeneic stem cell transplantation for chronic myeloid leukemia.

21 January 2018

1 reference

BCR-ABL transcripts are early predictors for hematological relapse in chronic myeloid leukemia after hematopoietic cell transplantation with reduced intensity conditioning

21 January 2018

1 reference

Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.

21 January 2018

1 reference

Successful allogeneic stem cell transplantation in second chronic-phase CML induced by the tyrosine kinase inhibitor nilotinib (AMN107) after blast crisis under imatinib

21 January 2018

1 reference

Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis

21 January 2018

1 reference

Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1159/000323662

1 reference

24 August 2017

1 reference